Silent pheochromocytoma and paraganglioma: Systematic review and proposed definitions for standardized terminology.

Georgiana Constantinescu, Cristina Preda, Victor Constantinescu, Timo Siepmann, Stefan R Bornstein, Jacques W M Lenders, Graeme Eisenhofer, Christina Pamporaki

Journal: Frontiers in endocrinology 2022;13():1021420

PMID: 36325453

Abstract

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors with heterogeneous clinical presentations and potential lethal outcomes. The diagnosis is based on clinical suspicion, biochemical testing, imaging and histopathological confirmation. Increasingly widespread use of imaging studies and surveillance of patients at risk of PPGL due to a hereditary background or a previous tumor is leading to the diagnosis of these tumors at an early stage. This has resulted in an increasing use of the term "silent" PPGL. This term and other variants are now commonly found in the literature without any clear or unified definition. Among the various terms, "clinically silent" is often used to describe the lack of signs and symptoms associated with catecholamine excess. Confusion arises when these and other terms are used to define the tumors according to their ability to synthesize and/or release catecholamines in relation to biochemical test results. In such cases the term "silent" and other variants are often inappropriately and misleadingly used. In the present analysis we provide an overview of the literature and propose standardized terminology in an attempt at harmonization to facilitate scientific communication.

Copyright © 2022 Constantinescu, Preda, Constantinescu, Siepmann, Bornstein, Lenders, Eisenhofer and Pamporaki.

Address: Department of Endocrinology and Diabetes, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Department of Endocrinology, Grigore T. Popa University, Iasi, Romania.; Department of Health Care Sciences, Center for Clinical Research and Management Education, Dresden Inter-national University, Dresden, Germany.; Center of Clinical Neuroscience, University Clinic Carl-Gustav Carus, Dresden University of Technology, Dresden, Germany.; Department of Neurology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.; Department of Health Care Sciences, Center for Clinical Research and Management Education, Dresden International University, Dresden, Germany.; Division of Diabetes & Nutritional Sciences, Faculty of Life Sciences & Medicine, King's College London, London, United Kingdom.; Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, Netherlands.; Institute of Clinical Chemistry and Laboratory Medicine, University of Dresden, Dresden, Germany.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.